{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:26:21Z","timestamp":1749939981947,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09734003"],"award-info":[{"award-number":["2018ZX09734003"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872902","82073917","82103579","82104273"],"award-info":[{"award-number":["81872902","82073917","82103579","82104273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00277-023-05541-7","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T02:02:02Z","timestamp":1699840922000},"page":"793-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study"],"prefix":"10.1007","volume":"103","author":[{"given":"Peng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baitian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-0371","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"5541_CR1","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690\u20132697. https:\/\/doi.org\/10.1200\/JCO.2016.66.4482","journal-title":"J Clin Oncol"},{"key":"5541_CR2","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, Roemer M, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420\u20132430. https:\/\/doi.org\/10.1182\/blood-2017-03-770719","journal-title":"Blood"},{"key":"5541_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68:116\u2013132. https:\/\/doi.org\/10.3322\/caac.21438","journal-title":"CA Cancer J Clin"},{"key":"5541_CR4","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, Sun A, Hodgson DC (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49:1486\u20131493. https:\/\/doi.org\/10.1080\/10428190802140873","journal-title":"Leuk Lymphoma"},{"key":"5541_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","volume":"6","author":"P Lorigan","year":"2005","unstructured":"Lorigan P, Radford J, Howell A, Thatcher N (2005) Lung cancer after treatment for Hodgkin\u2019s lymphoma: a systematic review. Lancet Oncol 6:773\u2013779. https:\/\/doi.org\/10.1016\/S1470-2045(05)70387-9","journal-title":"Lancet Oncol"},{"key":"5541_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134:1144\u20131153. https:\/\/doi.org\/10.1182\/blood.2019000324","journal-title":"Blood"},{"key":"5541_CR7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36:1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"key":"5541_CR8","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","volume":"37","author":"R Ramchandren","year":"2019","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A, Trn\u011bn\u00fd M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol 37:1997\u20132007. https:\/\/doi.org\/10.1200\/JCO.19.00315","journal-title":"J Clin Oncol"},{"key":"5541_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/JCO.22.02355","volume":"41","author":"PJ Br\u00f6ckelmann","year":"2023","unstructured":"Br\u00f6ckelmann PJ, B\u00fchnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B (2023) Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin study group phase II NIVAHL trial. J Clin Oncol 41:1193\u20131199. https:\/\/doi.org\/10.1200\/JCO.22.02355","journal-title":"J Clin Oncol"},{"key":"5541_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","volume":"137","author":"PB Allen","year":"2021","unstructured":"Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer RA, Eisner RM, Chmiel JS, O\u2019Shea K, Gordon LI, Winter JN (2021) Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 137:1318\u20131326. https:\/\/doi.org\/10.1182\/blood.2020007400","journal-title":"Blood"},{"key":"5541_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1358\/dot.2020.56.12.3233362","volume":"56","author":"J Chen","year":"2020","unstructured":"Chen J, Zhang H, Zhu L, Zhao Y, Ding Y, Yuan Y (2020) Tislelizumab for the treatment of classical Hodgkin\u2019s lymphoma. Drugs Today (Barc) 56:781\u2013785. https:\/\/doi.org\/10.1358\/dot.2020.56.12.3233362","journal-title":"Drugs Today (Barc)"},{"key":"5541_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","volume":"28","author":"Y Song","year":"2022","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Zhao X, Wang D, Zhang P, Wang Y, Wang L, Liu T, Zhang Y, Shen Z, Huang J, Zhu J (2022) Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. Clin Cancer Res 28:1147\u20131156. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2023","journal-title":"Clin Cancer Res"},{"key":"5541_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, Zhang Y, Zhou X, Wang Z, Wang Y, Shi Y, Bai H, Liu N, Yang X, Cui X, Cao Y, Liu Q, Song J, Li Y, Tang Z, Guo M, Wang L, Li K (2018) The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother 67:1079\u20131090. https:\/\/doi.org\/10.1007\/s00262-018-2160-x","journal-title":"Cancer Immunol Immunother"},{"key":"5541_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28:285\u2013295. https:\/\/doi.org\/10.1016\/j.ccell.2015.08.004","journal-title":"Cancer Cell"},{"key":"5541_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J (2020) Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia 34:533\u2013542. https:\/\/doi.org\/10.1038\/s41375-019-0545-2","journal-title":"Leukemia"},{"key":"5541_CR16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010334","author":"SM Ansell","year":"2023","unstructured":"Ansell SM, Br\u00f6ckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trn\u011bn\u00fd M, Provencio M, Jaeger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert AM, Armand P (2023) Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase 2 CheckMate 205 study. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2023010334","journal-title":"Blood Adv"},{"key":"5541_CR17","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","volume":"108","author":"K Ding","year":"2023","unstructured":"Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, Peng H, Shi W, Zhao X, Wu W, Zhu H, Li J, Fan L (2023) Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 108:2146\u20132154. https:\/\/doi.org\/10.3324\/haematol.2022.282266","journal-title":"Haematologica"},{"key":"5541_CR18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, S\u00f6kler M, Kerkhoff A, Mathas S, H\u00fcttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A (2020) Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol 6:872\u2013880. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750","journal-title":"JAMA Oncol"},{"key":"5541_CR19","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1182\/bloodadvances.2022007363","volume":"6","author":"KL Chohan","year":"2022","unstructured":"Chohan KL, Young JR, Lester S, Alhaj Moustafa M, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM (2022) A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv 6:4241\u20134250. https:\/\/doi.org\/10.1182\/bloodadvances.2022007363","journal-title":"Blood Adv"},{"key":"5541_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.hemonc.2019.08.009","volume":"13","author":"ZW Myint","year":"2020","unstructured":"Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R, Monohan GP, Hildebrandt GC, Saeed H (2020) Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: an analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther 13:17\u201322. https:\/\/doi.org\/10.1016\/j.hemonc.2019.08.009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"5541_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40164-022-00360-4","volume":"11","author":"W Hanel","year":"2022","unstructured":"Hanel W, Herrera AF, Epperla N (2022) Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Exp Hematol Oncol 11:108. https:\/\/doi.org\/10.1186\/s40164-022-00360-4","journal-title":"Exp Hematol Oncol"},{"key":"5541_CR22","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Sch\u00e4fer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, D\u00fchrsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol 37:2835\u20132845. https:\/\/doi.org\/10.1200\/JCO.19.00964","journal-title":"J Clin Oncol"},{"key":"5541_CR23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O\u2019Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"5541_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","volume":"128","author":"A Kumar","year":"2016","unstructured":"Kumar A, Casulo C, Yahalom J, Sch\u00f6der H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH (2016) Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 128:1458\u20131464. https:\/\/doi.org\/10.1182\/blood-2016-03-703470","journal-title":"Blood"},{"key":"5541_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1634\/theoncologist.2017-0541","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Sun H, Yan Y, Sun T, Wang S, Ma H (2018) Long-term survival rates of patients with stage III-IV Hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984\u20132013. Oncologist 23:1328\u20131336. https:\/\/doi.org\/10.1634\/theoncologist.2017-0541","journal-title":"Oncologist"},{"key":"5541_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol 19:737\u2013746. https:\/\/doi.org\/10.1016\/S1470-2045(18)30261-4","journal-title":"Lancet Oncol"},{"key":"5541_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373\u2013377. https:\/\/doi.org\/10.1038\/nature14292","journal-title":"Nature"},{"key":"5541_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","volume":"108","author":"D Chen","year":"2020","unstructured":"Chen D, Verma V, Patel RR, Barsoumian HB, Cortez MA, Welsh JW (2020) Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials. Int J Radiat Oncol Biol Phys 108:196\u2013203. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5541_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.21037\/atm-22-2669","volume":"10","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Bi Y, Xue J, Liu Y, Zhu J, Qin S (2022) Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis. Ann Transl Med 10:744. https:\/\/doi.org\/10.21037\/atm-22-2669","journal-title":"Ann Transl Med"},{"key":"5541_CR30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/jcm8071014","volume":"8","author":"F Huemer","year":"2019","unstructured":"Huemer F, Lang D, Westphal T, Gampenrieder SP, Hutarew G, Weiss L, Hackl H, Lamprecht B, Rinnerthaler G, Greil R (2019) Baseline absolute lymphocyte count and ECOG performance score are associated with survival in advanced non-small cell lung cancer undergoing PD-1\/PD-L1 blockade. J Clin Med 8:1014. https:\/\/doi.org\/10.3390\/jcm8071014","journal-title":"J Clin Med"},{"key":"5541_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tjog.2022.08.021","volume":"62","author":"WJ Lee","year":"2023","unstructured":"Lee WJ, Wang YL, Peng HH, Lin CT (2023) Increased absolute lymphocyte count, increased absolute neutrophil count and low platelet to lymphocyte ratio as predicting factors in the superior disease control of refractory\/relapsing gynecologic malignancies with anti PD-1 therapy: 10 years of experience in a single institution. Taiwan J Obstet Gynecol 62:506\u2013509. https:\/\/doi.org\/10.1016\/j.tjog.2022.08.021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"5541_CR32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/DDDT.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, Sokol L, Agarwal R, Strafaci JA, O\u2019Neal M (2017) Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther 11:1719\u20131728. https:\/\/doi.org\/10.2147\/DDDT.S136988","journal-title":"Drug Des Devel Ther"},{"key":"5541_CR33","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05541-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05541-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05541-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:16:55Z","timestamp":1708168615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05541-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5541"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05541-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}}]}}